@article{51bf29734aa84254a01ca66c15a6d317,
title = "Transthyretin V122I in African Americans With Congestive Heart Failure",
author = "Joel Buxbaum and Jacobson, {Daniel R.} and Clement Tagoe and Alice Alexander and Kitzman, {Dalane W.} and Barry Greenberg and Surai Thaneemit-Chen and Philip Lavori",
note = "Funding Information: Please note: Dr. Buxbaum is presently a consultant to a company (FoldRx, Cambridge, Massachusetts) attempting to develop small molecule therapies for the transthyretin amyloidoses. He was not affiliated with the company when these studies were performed and the results analyzed. This research is supported in part by Grants R01-AG19259 (Dr. Buxbaum), NO1-HC-85079 to NO1-HC-85086, NO1-HC-35219, and NO1-HC-15103 from the National Heart, Lung, and Blood Institute (CHS), and the Department of Veterans Affairs, Merit Review funds, and an AHA Established Investigator Grant, 9740136N (Dr. Jacobson). A full list of participating CHS investigators and institutions is available at http:/www.chs-nhlbi.org . Dr. Marvin Konstam acted as guest editor for this article. ",
year = "2006",
month = apr,
day = "18",
doi = "10.1016/j.jacc.2006.01.042",
language = "English (US)",
volume = "47",
pages = "1724--1725",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "8",
}